1. pUDK-HGF Gene Therapy to Relieve CLI Rest Pain and Ulcer: A Phase II, Double-Blind, Randomized Placebo-Controlled Trial
- Author
-
Yiqing Li, Fengjun Xiao, Bonan Lv, Zhenming Qiu, Qinglin Zhang, Yongquan Gu, Jianhua Huang, Shijun Cui, Tingting Qin, Wenjie Sun, Jichun Zhao, Dan Zhu, Wenguang Zhao, Wei Guo, Changjian Liu, Yuxin Lu, Jun Zhao, Xinglong Yang, Li Du, Ping Yin, Zuze Wu, Keyun Ren, Xiaochen Cheng, Ming Li, Mingzhang Li, and Wen Huang
- Subjects
Chronic Limb-Threatening Ischemia ,medicine.medical_specialty ,Genetic enhancement ,Placebo-controlled study ,Pain ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Ischemia ,Internal medicine ,Genetics ,medicine ,Humans ,Molecular Biology ,Ulcer ,Rest (music) ,030304 developmental biology ,0303 health sciences ,Hepatocyte Growth Factor ,business.industry ,Genetic Therapy ,Critical limb ischemia ,Clinical trial ,030220 oncology & carcinogenesis ,Molecular Medicine ,Hepatocyte growth factor ,medicine.symptom ,business ,Intramuscular injection ,Growth Factor Gene ,medicine.drug - Abstract
This phase II clinical trial investigated the efficacy and safety of intramuscular injection of plasmid pUDK-HGF, which encodes the human hepatocyte growth factor gene in patients with critical limb ischemia. Resting pain patients (
- Published
- 2021
- Full Text
- View/download PDF